Monday, Jul 13, 2020 | Last Update : 10:36 PM IST

111th Day Of Lockdown

Maharashtra25442714032510289 Tamil Nadu138470895321966 Delhi112494899683371 Gujarat41906291982046 Karnataka3884315411686 Uttar Pradesh3647623334934 Telangana3467122482356 West Bengal3001318581932 Andhra Pradesh2916815412328 Rajasthan2439218103510 Haryana2124015983301 Madhya Pradesh1763212876653 Assam168071089541 Bihar1630511953125 Odisha13737875091 Jammu and Kashmir105135979179 Kerala7874409532 Punjab78215392199 Chhatisgarh4081315319 Jharkhand3760230831 Uttarakhand3537278647 Goa2453120714 Tripura206714212 Manipur16098960 Puducherry141873918 Himachal Pradesh121391610 Nagaland8453270 Chandigarh5594178 Arunachal Pradesh3601382 Meghalaya295452 Mizoram2311500 Sikkim164810
  Business   Companies  30 Jun 2020  Bharat Biotech’s COVID-19 vaccine gets nod for human trials

Bharat Biotech’s COVID-19 vaccine gets nod for human trials

REUTERS
Published : Jun 30, 2020, 4:12 pm IST
Updated : Jun 30, 2020, 4:12 pm IST

Human trials are scheduled to start across the country in July, developed and manufactured in Bharat Biotech’s facility in Hyderabad

 India's first COVID-19 vaccine gets nod for human trials. (AFP Photo)
  India's first COVID-19 vaccine gets nod for human trials. (AFP Photo)

Bharat Biotech’s COVID-19 vaccine has been approved for human trials, making it India’s first domestic candidate to get the green light from the government’s drug regulator as cases surge in a country with more than 1.3 billion people.

The Drug Controller General of India has approved the company’s application to conduct a Phase I and II clinical trial of Covaxin, which was developed along with the Indian Council of Medical Research’s National Institute of Virology, the company said in a statement on Monday.

Human clinical trials are scheduled to start across the country in July for the vaccine, which was developed and manufactured in Bharat Biotech’s facility at Genome Valley in Hyderabad, India.

India, which lags only the United States, Brazil and Russia in total cases, reported close to 20,000 new infections on Monday, according to data from the country’s federal Health Ministry.

More than 16,000 people have died from the disease since the first case in India in January — low when compared to countries with similar numbers of cases. But experts fear hospitals in the densely populated nation will be unable to cope with a steep rise in cases.

Tags: bharat biotech, covid-19 vaccine, human trials, drug regulator, coronavirus cases